Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroki Inada

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Stem Cell Reports|October 31, 2025
Activation of canonical Wnt signaling is required for efficient direct reprogramming into human hepatic progenitor cellsShizuka Miura, Kenichi Horisawa, Hiroki Inada, et al.
Journal of Gastroenterology|February 5, 2024
A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNATakehisa Watanabe, Sanae Hayashi, Yan Zhaoyu, et al.
International Journal of Clinical Oncology|September 19, 2024
Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancerHiroki Inada, Hideaki Miyamoto, Satoru Shinriki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitisHiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto, et al.
World Journal of Clinical Cases|January 4, 2021
Risk factors for <i>de novo</i> hepatitis B during solid cancer treatmentRie Sugimoto, Masayuki Furukawa, Takeshi Senju, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 9, 2021
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensityTakayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka, et al.
Journal of Gastroenterology|November 17, 2025
TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinomaHiroki Inada, Sotaro Kurano, Hideaki Miyamoto, et al.
Cancers|March 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular CarcinomaTakayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, et al.
Clinical Journal of Gastroenterology|June 27, 2021
Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinomaRie Sugimoto, Hiroki Inada, Yuki Tanaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 29, 2023
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinomaYoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Stem Cell Reports|October 31, 2025
Activation of canonical Wnt signaling is required for efficient direct reprogramming into human hepatic progenitor cellsShizuka Miura, Kenichi Horisawa, Hiroki Inada, et al.
Journal of Gastroenterology|February 5, 2024
A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNATakehisa Watanabe, Sanae Hayashi, Yan Zhaoyu, et al.
International Journal of Clinical Oncology|September 19, 2024
Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancerHiroki Inada, Hideaki Miyamoto, Satoru Shinriki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitisHiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto, et al.
World Journal of Clinical Cases|January 4, 2021
Risk factors for <i>de novo</i> hepatitis B during solid cancer treatmentRie Sugimoto, Masayuki Furukawa, Takeshi Senju, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 9, 2021
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensityTakayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka, et al.
Journal of Gastroenterology|November 17, 2025
TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinomaHiroki Inada, Sotaro Kurano, Hideaki Miyamoto, et al.
Cancers|March 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular CarcinomaTakayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, et al.
Clinical Journal of Gastroenterology|June 27, 2021
Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinomaRie Sugimoto, Hiroki Inada, Yuki Tanaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 29, 2023
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinomaYoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, et al.
Pageof 2